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ARTICLE
Bi-allelic GOT2 Mutations Cause a Treatable
Malate-Aspartate Shuttle-Related Encephalopathy
Clara D.M. van Karnebeek,1,2,3,19,21,* Ru´ben J. Ramos,3,4,21 Xiao-Yan Wen,5,6,21
Maja Tarailo-Graovac,7,8,21 Joseph G. Gleeson,9 Cristina Skrypnyk,10 Koroboshka Brand-Arzamendi,5
Farhad Karbassi,5 Mahmoud Y. Issa,11 Robin van der Lee,12 Britt I. Dro¨gemo¨ller,13,14 Janet Koster,15
Justine Rousseau,16 Philippe M. Campeau,16 Youdong Wang,5 Feng Cao,17 Meng Li,5 Jos Ruiter,15
Jolita Ciapaite,3,4 Leo A.J. Kluijtmans,3,18 Michel A.A.P. Willemsen,3,19 Judith J. Jans,3,4 Colin J. Ross,13
Liesbeth T. Wintjes,3,18,20 Richard J. Rodenburg,3,18,19,20 Marleen C.D.G. Huigen,3,18 Zhengping Jia,17
Hans R. Waterham,3,15 Wyeth W. Wasserman,12 Ronald J.A. Wanders,3,15 Nanda M. Verhoeven-Duif,3,4
Maha S. Zaki,11 and Ron A. Wevers3,18,*
Early-infantile encephalopathies with epilepsy are devastating conditions mandating an accurate diagnosis to guide proper manage-
ment.Whole-exome sequencingwas used to investigate the disease etiology in four children from independent families with intellectual
disability and epilepsy, revealing bi-allelicGOT2mutations. In-depthmetabolic studies in individual 1 showed low plasma serine, hyper-
citrullinemia, hyperlactatemia, and hyperammonemia. The epilepsy was serine and pyridoxine responsive. Functional consequences of
observed mutations were tested by measuring enzyme activity and by cell and animal models. Zebrafish andmouse models were used to
validate brain developmental and functional defects and to test therapeutic strategies. GOT2 encodes the mitochondrial glutamate
oxaloacetate transaminase. GOT2 enzyme activity was deficient in fibroblasts with bi-allelic mutations. GOT2, a member of the
malate-aspartate shuttle, plays an essential role in the intracellular NAD(H) redox balance. De novo serine biosynthesis was impaired
in fibroblasts with GOT2 mutations and GOT2-knockout HEK293 cells. Correcting the highly oxidized cytosolic NAD-redox state by
pyruvate supplementation restored serine biosynthesis in GOT2-deficient cells. Knockdown of got2a in zebrafish resulted in a brain
developmental defect associated with seizure-like electroencephalography spikes, which could be rescued by supplying pyridoxine in
embryo water. Both pyridoxine and serine synergistically rescued embryonic developmental defects in zebrafish got2a morphants.
The two treated individuals reacted favorably to their treatment. Our data provide a mechanistic basis for the biochemical abnormalities
in GOT2 deficiency that may also hold for other MAS defects.
Introduction
Infantile-onset encephalopathies with epilepsy often are
devastating disorders with major consequences for the life
of affected individuals and their families. Identification of
an underlying diagnosis is paramount for personalized
management. Although inborn errors of metabolism do
not represent themost common cause of these encephalop-
athies, their early identification is of utmost importance,
since many require targeted therapeutic measures beyond
that of common antiepileptic drugs, either to control sei-
zures or to decrease the chance of neurodegeneration.
Here we describe four affected individuals with a metabolic
encephalopathy with epilepsy due to a defect in the mito-
chondrial isoform of glutamate oxaloacetate transaminase
or aspartate aminotransferase (GOT; EC 2.6.1.1). This is
a pyridoxal 50-phosphate (PLP)-dependent enzyme that
exists as cytosolic (GOT1) and intramitochondrial (GOT2)
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isoforms. Both isoforms catalyze the reversible interconver-
sion of oxaloacetate and glutamate into aspartate and
a-ketoglutarate. These enzymes are part of the malate-
aspartate shuttle (MAS), a key player in intracellular
NAD(H) redox homeostasis (Figure 1).1,2 NADH produced
in cytosolic NAD-linked dehydrogenase reactions, mainly
during glycolysis, is re-oxidized to NADþ inside the mito-
chondria.3 Since the inner mitochondrial membrane is
relatively impermeable to NADþ and NADH,4 NAD(H)-
redox shuttles exist.3 The MAS provides a mechanism for
net transfer of NADH reducing equivalents across the inner
mitochondrial membrane.4 Defects in the MAS have been
described due to mutations in genes encoding mitochon-
drial malate dehydrogenase (MDH2 [MIM: 154100]) and
both aspartate-glutamate carriers (SLC25A12 [MIM:
603667], SLC25A13 [MIM: 603859]).5–9
We report GOT2 deficiency, a MAS disorder, and present
the clinical and biochemical phenotype of three unrelated
families, computational analyses, and experimental data
to validate the deleterious impact of the identified GOT2
(MIM: 138150) variants, as well as biomarkers and thera-
peutic strategies for this inborn error of metabolism.
Material and Methods
The Three Families
Family I was enrolled into the TIDEX gene discovery project (UBC
IRB approval H12-00067) and provided written consent for the
investigations and for publication of this manuscript. Written
informed consent was also obtained for the families II and III.
Whole-Exome Sequencing (WES) Analysis
Family I
Trio (proband-mother-father) whole-exome sequencing (WES)
was performed using the Agilent SureSelect kit and Illumina HiSeq
2000 (Perkin-Elmer). The sequencing reads were aligned to the
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Figure 1. Schematic Diagram Showing the Essential Role of the Malate-Aspartate NAD(H) Redox Shuttle in the Re-oxidation of
Cytosolic NADH
(A) The cytosol contains a variety of different NADH-generating dehydrogenases involved in glycolysis, serine biosynthesis, and other
pathways. Since the mitochondrion is the ultimate site of NADH-re-oxidation, the NADH generated in the cytosol needs to be shuttled
across the mitochondrial membrane. This is brought about by so-called NAD(H) redox shuttles, with the malate aspartate shuttle as the
most important one. The malate aspartate shuttle requires the concerted action of six different components: cytosolic and mitochon-
drial malate dehydrogenase (MDH1 andMDH2), cytosolic andmitochondrial glutamate aspartate transaminase (GOT1 and GOT2), and
the two mitochondrial solute carriers aspartate-glutamate (AGC1 and AGC2) and 2-oxoglutarate (OGC).
(B) Schematic diagram showing the consequences of an impairment in the malate-aspartate NAD(H) redox shuttle and the important
role of lactate dehydrogenase in the re-oxidation of the NADH generated in the cytosol. GAP, glyceraldehyde 3-phosphate; 1,3-DPG,
1,3-diphosphoglycerate; 3-PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
3-PGDH, 3-phosphoglycerate dehydrogenase; LDH, lactate dehydrogenase; NADþ, nicotinamide adenine dinucleotide (oxidized
form); NADH, nicotinamide adenine dinucleotide (reduced form); MIM, mitochondrial intermembrane space; ADP, adenosine diphos-
phate; ATP, adenosine triphosphate; Pi, inorganic phosphate; OXPHOS, oxidative phosphorylation.
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human reference genome version hg19 using Bowtie 210 and
mean coverage of 433 (proband), 323 (mother), and 483 (father)
was achieved. The data were further analyzed using our semi-auto-
mated bioinformatics pipeline:11 (1) the duplicates were marked
and sorted using Picard, (2) variants were called using SAMtools
and BCFtools after indel realignment using GATK, (3) transcripts
were annotated using snpEff,12 (4) functional variants were prior-
itized for rare variants by comparison against the public databases
dbSNP, NHLBI Exome Sequencing Project Exome Variant Server,
and Exome Aggregation Consortium [ExAC]), and (5) subse-
quently screened under a series of Mendelian inheritance models:
homozygous, hemizygous, compound heterozygous, and de novo
as described previously.11 The UCSC Genome Browser was used
to examine conservation of the affected amino acids, while the
protein domains in which the variants occurred was visualized
using the Lollipops software.13
Families II and III
WES was performed on affected probands of families II and III. In
family II, candidate missense variants were identified in three
genes—MUC19 (MIM: 612170), GOT2, and ZNF157 (MIM:
300024)—consistent with recessive mode of inheritance after
filtering and prioritization of the variants. Similarly, missense var-
iants in four genes—PRKAG3 (MIM: 604976), GOT2, ABCA10
(MIM: 612508), and DSG3 (MIM: 169615)—were identified in
family III. The variant had to be homozygous in all probands
with an allele frequency in gnomAD less than 0.01% and in the
Greater Middle eastern population of less than 1%. For consan-
guineous families, the variant was required to be present within
the linkage peak as defined by parametric linkage analysis
with LOD > 1.4 or in a ‘‘run of homozygosity’’ of at least 1 Mb.
In family II, the GOT2 variant (hg19:16: g.58750636G>C,
c.784C>G [p.Arg262Gly], GenBank: NM_002080.2:5166106)
was the only variant falling within the linkage peak with
LOD > 1.4.
Sequence Alignment
Sequences of GOT2 orthologs were identified using BLAST with
the human reference GOT2 protein sequence (GenBank:
NP_002071, corresponding to mRNA GenBank: NM_002080);
GOT2 orthologs date back as far as yeast. Sequences were selected
to cover a large phylogenetic distance. Multiple sequence align-
ments were calculated using MAFFT global alignment (mafft-
ginsi)14 and visualized using Jalview.15
Protein Modeling
The effects of theGOT2 variants on the protein structure and func-
tionwere analyzed using three-dimensional protein structures.We
modeled the variants based on a template structure of the mature
human GOT2 protein, solved as a homodimer complex at 3.0 A˚
resolution (PDB: 5AX8, chains A and C).16 As the human structure
lacked substrate and cofactor molecules, we also analyzed the
mature mouse GOT2 protein (PDB: 3PDB, chains A and B,
2.4 A˚)17 crystallized with oxaloacetate and pyridoxal 50-phosphate
(present in an intermediate state of catalysis as covalently bound
to Lys279). The human and mouse sequences and structures are
highly similar at 95% sequence identity and an average distance
between atoms <1 A˚ (root-mean-square deviation [RMSD]; super-
imposition of the protein structures). Therefore, ligand coordi-
nates from the mouse structure were transferred to the human
structure. The resulting PDB: 5AX8 template structurewith ligands
was submitted to SWISS-MODEL to model the GOT2 variants.18
Models were of overall high quality (global model quality estima-
tion [GMQE] ¼ 0.98). Structures were visualized with YASARA (see
Web Resources).
GOT2 Protein Expression
Western blot analysis on mutant and control fibroblasts of GOT2
and succinate dehydrogenase complex flavoprotein subunit A
(SDHA, a mitochondrial marker protein) was performed following
standard molecular biological procedures. Antibodies used are
a GOT2 polyclonal antibody (Bethyl A304-356A-T; diluted
1:1,000) with the secondary antibody Alexa Fluor-680-labeled
goat-anti-rabbit antibody (Invitrogen Cat. No. A21109) and a
monoclonal complex II SDHA antibody (Abcam cat. ab14715;
diluted 1:2,000) with the secondary goat-anti-mouse IRDye800
antibody (Rockland Cat. No. 610-132-121). Western blot analysis
on the HEK293 CRISPR/Cas9 cells was performed following stan-
dard biological procedures, using the b-actin polyclonal antibody
from Sigma (Cat. No. ABT1487; diluted 1:10,000) and the second-
ary antibody donkey anti-mouse IRD 680.
GOT2 Activity in Skin Fibroblasts
GOT activity was measured in mitochondria-enriched fractions
prepared from cultured skin fibroblasts from an affected individual
and three control subjects. For this purpose, 1 3 106 cells were
cultured in M199 medium supplemented with 10% FBS and anti-
biotics. Cells were harvested by trypsinization and resuspended in
ice-cold 10 mM Tris-Cl (pH 7.6). All subsequent steps were per-
formed at 4C. The cell suspension was homogenized by using a
Potter-Elvehjem homogenizer after which 0.2 vol of 1.5 M sucrose
was added. The suspension was centrifuged for 10 min at 600 3 g.
The supernatant was further centrifuged for 20 min at 20,000 3 g.
The mitochondria-enriched pellet was washed twice with 10 mM
Tris-Cl (pH 7.6), was resuspended in the same buffer, and was
stored at 80C until measurements were performed. Prior to
further measurements, 0.01% Triton X-100 was added and the
samples were freeze-thawed for three cycles. Protein concentra-
tions of the extracts were determined on a KoneLab 20XTi system
using a U/CSF protein kit (ThermoFisher). GOT activity was
measured using a commercial kit (Cat. No. 05531446) from Roche
Diagnostics (Roche Diagnostics), for the quantitative determina-
tion of glutamate oxaloacetate transferase with pyridoxal 50-phos-
phate activation on a Cobas C8000 analyzer (Roche Diagnostics).
The assay is based on the following reaction, which is catalyzed by
GOT in the mitochondrial protein extracts: 2-oxoglutarate þ
L-aspartate / L-glutamate þ oxaloacetate. This reaction is
coupled to the following reaction: oxaloacetate þ NADH þ Hþ
/ malate þ NADþ, catalyzed by malate dehydrogenase included
in the assay kit. The GOT activity in the sample is directly propor-
tional to the rate of NADH conversion, which is measured spectro-
photometrically at 340 nm. The experiment was performed in
duplicate.
Generation of GOT2-Knockout HEK293 Clones by
CRISPR/Cas9
The CRISPR/Cas9 genome editing technology as described by Ran
was used to introduce a disruption of the GOT2 gene in HEK293
cells.19 Oligonucleotide sequences coding for a guide RNA up-
stream of a proto-spacer adjacent motif (PAM) site in exon 2
(50-CCT, c.197_199) of GOT2 are available upon request. The
two oligos were annealed and subsequently cloned into the
pX458 (-pSpCasq(BB)-2A-GFP) plasmid,19 followed by Sanger
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sequencing of the insert to confirm the correct sequence. HEK293
cells were transfected with 2 mg plasmid, and single green fluores-
cent protein (GFP)-positive cells were sorted into wells of a 96-well
plate using fluorescence-activated cell sorting (FACS) flow cytom-
etry (S800HCell Sorter, Sony) as described.19 After 3–4weeks, DNA
was isolated from the expanded single colonies, and exon 2 of the
GOT2 gene was PCR amplified using Phire Hot Start II DNA Poly-
merase (ThermoFisher Scientific) according to the manufacturer’s
instructions and subsequently Sanger sequenced. Three clonal
CRISPR/Cas9 GOT2-knockout HEK293 cell lines were generated:
clone A3 was compound heterozygous for 205dup/202_203insA,
clone A6 for 205del/190_206del/203_206dup, and clone A7 ho-
mozygous for 205dup. There were no significant putative off-
target regions predicted by the online CRISPR design tool.
GOT2 Activity in the HEK293 CRISPR/Cas9 Cells
The GOT activity, in the HEK293 cells, was measured spectropho-
tometrically using a coupled assay method based on the NADH-
dependent conversion of oxaloacetate as generated from
L-aspartate by GOT, to malate mediated by malate dehydrogenase
added to the assay mixture. The absorbance at 340 nm was fol-
lowed for 30 min at 37C using a centrifugal analyzer (Hoffman
COBAS-FARA, Hoffman, LaRoche). The composition of the assay
mixture was as follows: 100 mM potassium phosphate buffer
(pH 7.4); 100 mM L-aspartate; 0.2 mM NADH; 0.1% (w/v)
Trition-X-100; 7.3 U/mL malate dehydrogenase and 25 mL of
cellular homogenate, in a final volume of 250 mL. The reactions
were started by adding 10 mM a-ketoglutarate to the assay
mixture.
Lentiviral Transduction of Mutant Fibroblasts with Wild-
Type GOT2
A synthetic GOT2 cDNA (GenBank: NM_002080) with stop codon
and attB sites was obtained from Thermo Fisher (ThermoFisher
Scientific). The DNA fragment was cloned into pDONR201 and
subsequently into pLenti6.2/V5-DEST by Gateway technology
cloning (Invitrogen). The resulting expression construct was
checked by Sanger sequencing. The construct was used for lentivi-
ral particle production by transfection into HEK293-FT cells, as
described before.20 The viral particle-containing supernatant was
used to transduce subconfluent fibroblasts with GOT2 mutations.
After selection with blasticidin (Invivogen), the resulting cell
culture was used for western blot and GOT enzyme activity assays.
As a control, the mutant cells were transduced with lentiviral par-
ticles from HEK293 cells transfected with a pLENTI construct with
a green fluorescent protein cDNA, as described before.20
Cell Culture
Dulbecco’s modified eagle medium (DMEM), high glucose, Gluta-
MAX, pyruvate (Cat. No. 31966); DMEM-no glucose (Cat. No.
11966); fetal bovine serum (FBS; Cat. No. 10270); penicillin-strep-
tomycin (P/S (10,000 U/mL); Cat. No. 15140) and trypsin-ethyle-
nediaminetetraacetic acid (trypsin-EDTA (0.5%), no phenol red;
Cat. No. 15400) were purchased from GIBCO (ThermoFisher Sci-
entific). Uniformly labeled 13C6-glucose (99%) was purchased
from Cambridge Isotope Laboratories. Glucose was purchased
from Sigma-Aldrich.
Fibroblasts and HEK293 cells (GOT2-WT; and GOT2-A3, -A6,
and -A7 knockout clones) were grown in 75 cm2 flasks and main-
tained in DMEM, high glucose, GlutaMAX, pyruvate (with 10%
heat-inactivated FBS and 1% P/S), in a humidified atmosphere of
5% CO2 at 37
C. Cells were passaged upon reaching confluence
and media was refreshed every 48 h.
Stable Isotope Analysis: De Novo Serine Biosynthesis
Cells were plated on 6-well plates (500,000 cells per well) and
allowed to grow for 4 days. Media was refreshed 24 and 72 h after
plating. On the fourth day, cells were either incubatedwith DMEM
medium without glucose (DMEM, Cat. No.11966; supplemented
with 10% FBS and 1% P/S), to which 25 mmol/L glucose or
25 mmol/L uniformly labeled 13C6-glucose was added. Cells were
harvested at t ¼ 0, 0.5, 4, and 10 h. To this end, cells were washed
twice with cold PBS (4C) and harvested by scraping with 1.5 mL
ice-cold methanol. The samples were transferred into a 1.5 mL
eppendorf tubes, centrifuged (16,200 3 g for 10 min at 4C) and
the supernatants were transferred to new 1.5 mL eppendorf tubes.
The samples were evaporated at 40C under a gentle stream of
nitrogen until complete dryness and reconstituted with 500 mL
of UPLC-grade methanol (room temperature). The reconstituted
samples were stored at 80C until amino acid analysis was
performed.
Recovery Studies on De Novo Serine Biosynthesis
The recovery studies on serine de novo biosynthesis were per-
formed by incubating cells with DMEM-no glucose medium, to
which we added 25 mmol/L 13C6-glucose, and 0, 2.5 or 5 mmol/L
of glycerol or pyruvate. Samples were collected as described before,
at t ¼ 0, 0.5, and 4 h.
Amino Acid Analysis
To quantify intracellular 13C3-serine and
13C2-glycine, we adapted
the UPLC-MS/MS method described by Prinsen et al.21 Apart from
not using internal standards to avoid interference with the signal
of 13C3-serine and
13C2-glycine, adapting the range of the calibra-
tors to our samples’ concentrations, and using quality control
(QC) samples that resembled the concentrations of our samples,
no further adaptations were needed for sample preparation or
analysis of the amino acids.
Generation of GOT/ Mice by CRISPR/Cas9
The following mutations GenBank: NM_002080.2:c.617_
619delTCT (p.Leu209del) and c.1009C>G (p.Arg337Gly) were
introduced into the mouse genome using the CRISPR/Cas9
method (Table S3). The gRNAs were selected using the Crispr guide
selection software from Feng Zhang’s laboratory (Web Resources;
Table S4). The gRNAs were subcloned into the pX330-U6-Chimer-
ic_BB-CBh-hSpCas9, a gift from Feng Zhang (Addgene plasmid
#42230). Repair templates (ssODN) were designed to insert the
desired mutations and ultramer DNA were synthesized by Inte-
grated DNA Technologies (IDT). The Got2emhD335fs14* was
generated while making Got2emhR337G mice as a results of
unrepair indels. Both mice were generated by the Institut de
Recherches Cliniques de Montre´al (IRCM). Briefly, about 2 picoli-
ter of ssODN (100 mL/ng) and pX330-U6-Got2-hSpCas9 plasmid
(10 ng/mL) in 5 mM Tris, 0.02 mM EDTA was microinjected into
a pronucleus of C57BL/6J or B6C3F1 mouse zygotes that were
transferred into the oviduct of CD-1 pseudopregnant surrogate
mothers according to the standard approved animal user protocols
IRCM 2014-17. The Got2emhL209del was generated by the
McGill transgenic core facility. Briefly, the gRNA was transcribed
in vitro using the MAXIscript T7 kit (ThermoFisher, AM1312).
About 2 picoliter of gRNA (20 ng/mL), ssODN (100 ng/mL), and
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Cas9 RNA (50 ng/mL) were microinjected into a pronucleus of
C57BL/6N mouse zygotes and subsequently implanted in CD-1
pseudopregnant surrogate mothers according to the standard
approved animal user protocols #4437.
After weaning, the mice were transferred to the Centre de
Recherche du Centre Hospitalier Universitaire (CR-CHU) of
Sainte-Justine Hospital. Mouse husbandry and experiments were
done according to the approved animal user protocols #541 by
the Coordonnatrice du Comite´ Institutionnel des Bonnes
Pratiques Animales en Recherche (CIBPAR). This committee is
following the guidelines of the Conseil Canadien de la Protection
des Animaux (CCPA).
Zebrafish Husbandry
Zebrafish were maintained at 28.5C in a 10/14-h dark/light cycle.
Protocols for experimental procedures were approved by the
Ethics Board at St. Michael’s Hospital, Toronto, Canada (Protocol
ACC660).
Morpholino Knockdown
To knock down gene expression, we designed and injected oligonu-
cleotide morpholinos targeting the first ATG start codon as well as
the splicing (sp) donor site of the exon 2 for got2a. A standard con-
trol MO (Cont MO) was used as control. The MO sequences are as
follows: got2a atg-MO, 50-CTTGCTGGATTTGAACAGGGCCATT-30;
got2a sp-MO, 50-AGCTATTTAATATCACACCTTTCGA-30; and stan-
dard control MO, 50-CCTCTTACCTCAGTTACAATTTATA-30.
MOs were designed by Gene Tools. Normally we injected indi-
vidually 4 nL of got2a atg (8 ng/mL) and 4 nL of got2a sp
(16 ng/mL) MOs. Each injection was repeated at least three times.
For phenotype severity rescue experiments, ATG-blocking MO
solutions were prepared at 0.4 mM final concentration. 2 nL of
MO solution was injected in each embryo. For survival rescue
experiments, 4 nL of 0.8 mM MO solution was used.
Molecular Validation of got2a Splicing Morpholino
Knockdown
Knockdown of got2a with sp-MO was confirmed by RT-PCR.
Embryos were injected at 1 cell stage with 4 nL of got2a sp-MO
(16 ng/mL), the MO was diluted in water and phenol red. At
24 hpf, embryos were manually dechorionated. Total RNA was ex-
tracted from embryos at 24 and 48 hpf using TRIzol (Invitrogen).
The RNA concentration of each sample was quantified using a
NanoDrop ND-1000 spectrophotometer (NanoDrop Technolo-
gies). RNA integrity was verified in 1% agarose gel electrophoresis
(Invitrogen). The RNA template was converted into cDNAusing Su-
perscript II reverse transcriptase (Invitrogen). The primers used are
as follows: forward primer, 50-GCAATGGCCCTGTTCAAATC-30;
reverse primer, 30-CTGCATGCCTGCATCTCTAA-50.
Compound Rescue Experiments
Pyridoxine (P5669), serine (S4375), sodium pyruvate (P2256), and
L-proline (P0380) were purchased from Sigma-Aldrich. Zebrafish
embryos were distributed in 24-well plates (10 embryos per well
per condition). At 6 hpf, the embryos were treated with one of
the following compounds: 25 mM of pyridoxine, 2 mM of serine,
0.5 mM of sodium pyruvate, and 0.2 mM of L-proline. The plates
were kept at 28C. Survival and phenotypic assays were performed
at 1, 2, and 3 day post fertilization (dpf). The compound solutions
were replaced with the corresponding fresh solutions at 1 and
2 dpf. For survival assay, heartbeat and embryo movement were
considered at 2 dpf. For phenotypic assay, five phenotypes
(P1, P2, P3, P4, and P5) were characterized at 3 dpf based on the
severity (Figure 5A). For phenotype severity calculation, the
following ‘‘phenotype scores’’ were used: P0 (normal) ¼ 0,
P1 ¼ 1, P2 ¼ 2, P3 ¼ 3, P4 ¼ 4, P5 (dead) ¼ 5. Average phenotype
severity was calculated with the following formula:
Average phenotype severity ¼
X
n x ðPhenotype scoreÞ=N
where n ¼ number of embryos showing a specific phenotype in a
well, N ¼ total initial number of embryos in a well. Treated sam-
ples were compared to non-treated conditions using one-way
ANOVA test.
Electroencephalogram (EEG)
EEG recordings of zebrafish embryos were performed according to
a previously reportedmethod.22,23 Lowmelting 1.2% agarose (Bio-
Shop) was placed within recording media solution (1 mM NaCl,
2.9 mM KCl, 10 mM HEPES, 1.2 mM MgCl2, 10 mM dextrose,
2.1 mM CaCl2). Embryos were anesthetized with 0.02% tricaine
(Sigma Aldrich). Embryos in the agarose block were immersed in
recording media solution. A microelectrode (1 mm diameter,
2–7 MU) was mounted on a micromanipulator and inserted into
the front brain of zebrafish embryo at 2 dpf. Microelectrodes
were fabricated from 1.5 mm OD borosilicate glass and pulled
into two needles with a two-step Narishige micropipette puller.
The microelectrode was back loaded with recording media solu-
tion using a 1 mL syringe with a Corning syringe filter (0.2 mm),
and a 28-gauge MicroFil filament (World Precision Instruments)
was attached. Electrical activity was captured with an Axopatch
200B (Axon Instrument) patch clamp amplifier in current clamp
mode. Data were collected in pClamp 8 software (Molecular De-
vices) in gap-free acquisition mode, sampling at 10 kHz, and
gain at 100 mV/pA. A recording chamber and electrophysiology
rig were used to stabilize embryos. EEG was analyzed as number
of events and duration of each event for a single embryo. The
average of number of evens and event duration were calculated
for each embryo.
Rescue of Seizures in got2a sp-MO by Pyridoxine
At 2 h after got2a sp-MO injection, 25 mM of pyridoxine was
added to the embryo water in a 12-well plate and incubated at
28C. After 24 h of incubation, chorions were removed manually.
The medium and pyridoxine were refreshed after 24 hpf. At 48
hpf, the embryos were analyzed by electroencephalogram.
Results
Clinical History
Four individuals from three unrelated families (P1–P4; Ta-
ble 1; families I, II, and III; Figures 2A–2C) suffered from
similar clinical features, albeit of different severity: progres-
sive microcephaly, failure to thrive and feeding difficulties,
a metabolic encephalopathy with epilepsy from the first
year of life, and subsequent intellectual and motor disabil-
ities. Cerebral imaging showed cerebral atrophy and white
matter abnormalities in all four individuals. Biochemically,
high plasma lactate and hyperammonemia were found.
In individual 1, who was most severely affected, plasma
serine was low and citrulline high; his seizure control
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Table 1. Clinical, Biochemical, and Genetic Characteristics of the GOT2-Deficient Individuals
Individual 1, Family 1 Individual 2, Family II Individual 3, Family II Individual 4, Family III
Clinical History
Gender M F F M
Age (years) 8 10 8 4
Ethnicity Romanian Egyptian Egyptian Egyptian
Parental consanguinity  þ þ þ
Unaffected siblings 0 1 1 0
Siblings first child was stillborn first child spontaneous
abortion
first child spontaneous
abortion
sister died at age of 5 months
Delivery Caesarean section NVD NVD NVD
Gestational age (weeks) 38 32 38 39
Birth length percentile 85th <1st 5th 50th
Birth weight percentile 3rd <1st 5th 5th
Birth HC percentile 5th <1st 15th 15th
Apgar scores 9 5 8 6
Neonatal period  artificial ventilation
(first 20 days)
 
Hypotonia (neonatal) þ þ þ þ
Neonatal feeding difficulties þ þ þ (mild) þ
Frequent infections þ þ þ þ
Seizure onset 9 months 7 months 6 months 4 months
Seizure frequency 10–100 per day daily daily 20 per day
Seizure semiology upward gaze, clonic seizures
at upper limbs (left 5 right),
head tilting to left, and facial
clonic movements
myoclonic, GTC, tonic myoclonic, GTC myoclonic, tonic with
upward gaze
Pyridoxine supplementation þ   þ
Serine supplementation þ   þ
Progressive microcephaly þ þ þ þ
MRI findings multicystic encephalomalacia,
cerebral atrophy
mild cerebral atrophy
with a hypoplastic
vermis and a thin
corpus callosum
mild cerebral atrophy
with a hypoplastic
vermis and a thin
corpus callosum
(mainly frontoparietal)
asymmetric dilated lateral
ventricles; hypoplastic vermis;
corpus callosum hypoplasia
EEG findings  tempoparietal spikes tempoparietal spikes bilateral frontoparietal
frequent spikes
Metabolic Screening
Age 14 months 10 years 8 years 4 years
Amino acids (blood) abnormal normal normal normal
Serine (ref. value) (mmol/L) 47 (70–294) 114 (88–172) 171 (88–178) 130 (88–178)
Glycine (ref. value) (mmol/L) 280 (80–340) 184 (167–338) 295 (156–328) 273 (156–328)
Citrulline (ref. value)
(mmol/L)
89 (7–55) 37 (20–46) 36 (21–43) 27 (21–43)
Organic acids (urine) normal profile normal profile normal profile normal profile
Acylcarnitine (blood) normal profile normal profile normal profile normal profile
(Continued on next page)
The American Journal of Human Genetics 105, 534–548, September 5, 2019 539
and neurodevelopment improved considerably on pyri-
doxine and L-serine supplementation to the extent that
antiepileptic drugs could be stopped (Supplemental Note,
Table 1). Also, individual 4 in whom treatment was started
reacted favorably. His seizures diminished on pyridoxine
only and were fully controlled by the combined treatment
with pyridoxine and serine supplementation (Supple-
mental Note).
Exome Sequencing and Protein Structural Modeling to
Identify GOT2 Damaging Mutations
Nine candidate genes with rare, non-synonymous genetic
variants were identified by Trio WES on family I. GOT2 was
considered the best candidate to explain the biochemical
phenotype of the proband. The gene contained (1) a
paternally inherited in-frame deletion hg19:16: g.58752177
delGAA (p.Leu209del [c.617_619delTTC], GenBank:
NM_ 002080) and (2) amaternally inheritedmissensemuta-
tion hg19:16 g.58749928G>C (p.Arg337Gly [c.1009C>G]).
Both variants are not present in dbSNP (version 142), NHLBI
ESP, ExAC, gnomAD, or in our in-house genome database
comprising more than 11,450 exome and genome se-
quences. Exome sequencing was also used for the probands
of the other families. Three homozygous candidatemissense
variantswereprioritized in theprobands in family II and four
in family III. Homozygous GOT2 missense variants for the
families II and III were hg19:chr16: g.58750636G>C
(c.784C>G [p.Arg262Gly], GenBank: NM_002080) and
g.58743394C>A (c.1097G>T [p.Gly366Val]), respectively.
The allele frequencies in gnomADwere<0.01% and, within
gnomAD, in the Greater Middle Eastern population <1%.
The presence and family segregation of all GOT2 variants
was confirmed with Sanger sequencing.
All variants affect evolutionary highly conserved amino
acids (Figures 2D, S1, and S2, and Supplemental Data).
They are predicted to be damaging by in silico methods
(Table 1).24–27 Modeling of the variants in the GOT2 3-
dimensional protein structure (Figure 2E) suggests that
they reduce the catalytic activity of the enzyme and may
impact the overall protein conformation, both of which
may result in reduced levels of functional protein
(Figure 2E; detailed analysis in Supplemental Data).
Table 1. Continued
Individual 1, Family 1 Individual 2, Family II Individual 3, Family II Individual 4, Family III
Clinical Chemistry
Age 8 months 9 years 7 years 3 years
Blood lactate (ref. value)
(mmol/L)
5.7 (0.7–2.1) 4.2; 3 (0.5–2.2) 3.9 (0.5–2.2) 4.5 (0.5–2.2)
Blood ammonia (ref. value)
(mmol/L)
143 (16–60) 110 (<80); 70 (11–32) 120 (<80) 120 (<80)
Last visit
Age 7 years 10 years 8 years 4 years
Length percentile <1st <1st <1st 25th
Weight percentile <1st <1st 1st 25th
HC percentile <3rd <1st <1st <1st
Intellectual disability profound severe severe profound
Speech no words <10 single words no words no words
Motor disability severe spastic quadriplegia,
wheelchair bound
spastic paraparesis,
walks short distances
with support
spastic paraparesis,
wheelchair bound
severe spastic quadriplegia,
wheelchair bound
GOT2 variants
compound heterozygous homozygous homozygous homozygous
amino acid change p.Leu209del p.Arg337Gly p.Arg262Gly p.Arg262Gly p.Gly366Val
In silico Prediction
CADD 23.0 23.8 32.0 32.0 33.0
PROVEAN; cutoff: 2.5 na 4.25 (‘‘damaging’’) 6.7 (‘‘damaging’’) 6.7 (‘‘damaging’’) 8.54 (‘‘damaging’’)
PolyPhen2 na 0.922 (‘‘possibly
damaging’’)
1.0 (‘‘probably
damaging’’)
1.0 (‘‘probably
damaging’’)
0.993 (‘‘possibly damaging’’)
SIFT; cutoff: 0.05 na 0.243 (‘‘tolerated’’) 0 (‘‘damaging’’) 0 (‘‘damaging’’) 0 (‘‘damaging’’)
M, male; F, female; C-section, Caesarean section; NVD, normal vaginal delivery; NICU, neonatal intensive care unit; GTC, generalized tonic-clonic seizures; EEG,
electroencephalogram; MRI, magnetic resonance imaging; HC, head circumference; na, not available.
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ELegend:
Male Female Stillbirth
Male proband Female proband
Spontaneous abortion
A
I
II
P1
B
I
II
P2 P3
C
I
II
P4
D
H. sapiens
P. troglodytes
M. musculus
C. lupus
B. taurus
G. gallus
X. tropicalis
D. rerio
D. melanogaster
C. elegans
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N N ED L R AQW L K
SN P E L K K SW L E
SN P A L R EQWA G
ED P E L K S L W L K
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GOT2 430301 Aminotransferase class I/II domain
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(copy B)
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(copy A)
Arg337
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Gly366
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Active site
Gly366
Arg337
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60°
Leu207
Reference
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OAA
His210
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Asp255
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Figure 2. The Pedigrees and the GOT2 Variants
(A–C) Pedigrees of the families I–III.
(D) Alignment of GOT2 ortholog sequences. p.Leu209del represents the deletion of a leucine in a tri-leucine stretch. Figure S1 shows the
full alignment.
(E) Molecular modeling of the variants. Shown are rotated overview structures of the GOT2 homodimer complex, with variants found in
affected individuals shown in orange. Insets: p.Gly366Val (top left), p.Arg337Gly and p.Arg262Gly (bottom left; glycine substitutions
not visible), p.Leu209del (bottom right; reference structure in blue and variant model in orange superimposed). While visualized in a
single structure, variants are not simultaneously present in the same copy of the gene. Models are based on template structure PDB:
5AX8, with ligand coordinates taken from PDB: 3PDB. PMP, pyridoxamine 50-phosphate; OAA, oxaloacetate. Hydrogen bonds in yellow;
other charge interactions as dashed lines. p.Leu209del shortens a beta strand in the protein core close to the active site, leading to a
(legend continued on next page)
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GOT2 Deficiency in Fibroblasts and GOT2-Knockout
HEK293 Cells
Western blot analysis revealed that GOT2 was strongly
deficient in fibroblasts of individual 1 and to a lesser extent
in individuals 2–4 (Figure 3A). Three clonal CRISPR/Cas9
GOT2-knockout HEK293 cell lines were successfully
generated: clone A3 was compound heterozygous for
205dup/202_203insA, clone A6 for 205del/190_206del/
203_206dup, and clone A7 was homozygous for 205dup.
Western blot analysis performed on the three clonal cell
lines showed that GOT2 was not detectable in any of the
clones (Figure 3B).
GOT2 enzymatic activity was determined in mitochon-
dria-enriched fractions. In individuals 1–4 it amounted to
8%, 21%, 21%, and 18% of the mean of control subjects,
respectively. The two GOT2-carriers (1 and 2) had a resid-
ual activity of 39% and 62%, respectively (Figure 3C).
GOT enzymatic activity measurements in whole-cell
lysates prepared from the three different GOT2-knockout
clonal cell lines, which includes the combined activity of
both GOT1 and GOT2, was found to be markedly
decreased (p < 0.01) compared to GOT activity in wild-
type cells (Figure 3D). In addition, GOT2 activity in the
mitochondrial fraction was less than 2% of the activity
measured in control mitochondrial fractions (Figure 3E).
To investigate whether the defect could be rescued by
wild-type GOT2 cDNA, fibroblasts of individual 1 were
transduced using lentiviral particles with wild-type GOT2.
After selection of transduced cells, GOT enzyme activity
was measured in mitochondrial preparations showing a
strong increase of the mitochondrial GOT activity to levels
that fall within the range measured in control cells. The
control transduction experiment showed little or no effect
on GOT2 activity of the cells (Figure 3F).
De Novo Serine Biosynthesis in Fibroblasts and
GOT2-Knockout HEK293 Cells
Because themost important clinical finding in individual 1
were serine- and pyridoxine-responsive seizures, we evalu-
ated the impact of GOT2 deficiency on de novo serine
biosynthesis. Formation of stable isotope-labeled serine
from labeled glucose was analyzed in fibroblasts of all
GOT2-deficient individuals, two GOT2 carriers, six control
subjects, and fibroblasts from individuals with a defect in
serine biosynthesis (phosphoserine aminotransferase defi-
ciency [PSATD] [MIM: 610992] and 3-phosphoglycerate
dehydrogenase deficiency [3-PDGHD] [MIM: 608015]).
The fibroblasts of the GOT2-deficient individuals 1 and 4
formed less 13C3-serine amounting to 34% and 33% of
control subjects, respectively. Individuals 2 and 3 produced
55% and 52% of control subjects, respectively. In addition,
the GOT2-carrier 1 produced 66% of 13C3-serine, while the
GOT2-carrier 2 produced almost as much as control s
(81%). In fibroblasts from 3-PGDHD- and PSATD-deficient
individuals, de novo serine biosynthesis amounted to 15%
and 0%, respectively (Figure 4A).
Analysis of de novo serine biosynthesis in GOT2-
knockout cell lines revealed that the three GOT2-knock-
outs had a severe reduction in 13C3-serine production
(90%–93%). In addition, 13C2-glycine synthesis was
reduced by 87%–88% (Figure 4B).
We hypothesized that the GOT2 defect would result in
decreased MAS activity resulting in an increased NADH/
NADþ ratio in the cytosol. To investigate whether restoring
the cytosolic redox imbalance would correct the serine
biosynthesis capacity of the cells, we incubated the
GOT2-knockout cell line A3 with glycerol and pyruvate.
Supplementation of the culture medium with 2.5 and
5 mmol/L glycerol had no effect on serine biosynthesis.
However, serine and glycine synthesis was fully restored
when cells were incubated with 2.5 or 5 mmol/L pyruvate,
the substrate of lactate dehydrogenase (LDH; Figures 4C
and 4D). This effect is explained by the re-oxidation of
cytosolic NADH by LDH.
CRISPR/Cas9 Got2-Knockout Mice
We generated mice heterozygous for the p.Arg337Gly and
p.Leu209del mutations, and for a loss-of-function muta-
tion (p.Asp335fs14*). These mice were viable and healthy,
similarly to the parents of the four affected individuals.
Unfortunately, no homozygous mice for any of these
mutations were viable beyond early pregnancy (Table
S5). Mouse embryonic fibroblasts (MEFs) were collected
at the age of 14 days post coitum (dpc) and genotyped.
No homozygous embryos were found suggesting early
lethality for all three mutations in mice (Table S6).
Knockdown of got2a in Zebrafish Affects Embryonic
Development and Provokes Seizure-like EEG Spikes,
which Is Rescued by Pyridoxine and Serine
While CRISPR-based gene knockout is currently widely
used to study gene function, however, gene knockdown
technologies are still vital methods evaluating gene contri-
bution to diseased phenotypes as the majority of human
genemutations retain residual gene activities at various de-
grees. Furthermore, there are essential genes that could not
be fully knocked out in the organism and GOT2 could be
one of these genes. Using the morpholino-based gene
knockdown strategy, our previous studies had led to func-
tional characterization of a number of genes in metabolic
diseases.28,29 As the knockout of Got2 in mice is embryonic
lethal, we knocked down the zebrafish mitochondrial
got2a gene by ATG- and splicing-blocking morpholinos
(MO) (see Figure S3 for details regarding specificity of
repositioning of loops involved in the geometry of the catalytic pocket, likely affecting binding of both the enzyme cofactor (pyridoxal
50-phosphate) and substrates. p.Gly366Val has a predicted marginal effect on the protein structure, but is still well conserved across
evolution. For p.Arg337Gly and p.Arg262Gly, substitution of the positively charged arginine residues with the neutral glycine residue
results in a disruption of electrostatic interactions that in the wild-type protein stabilize the a-helical organization of the protein.
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knocking down got2a). While 18% of the embryos injected
with got2a MO showed a mild phenotype at 48 h post
fertilization (hpf), many other morphants showed a small
head, slow circulation, bend body, and pericardial edema.
Bright field imaging confirmed brain developmental
defects (Figure 5A). To establish a quantitative measure
for rescue of the got2a-MO phenotypes, we developed a
scoring system to define the phenotype severity in five cat-
egories from P1 to P5 (very mild to embryonic death,
Figure 5A). In exploring therapeutic methods, we dosed
various concentrations and combinations of pyridoxine
(PN), serine, pyruvate, and proline in embryo water of
the got2a morphants. In non-toxic doses to embryos,
25 mM PN and 2 mM serine significantly rescued the
phenotype severity (p < 0.01). PN and serine had a syner-
gistic effect (3 mM PN þ 0.25 mM serine); noticeably
0.5 mM pyruvate also has some rescuing effect (p < 0.05;
Figure 5B). However, only PN and serine rescue the survival
phenotype as scored by beating hearts (Figure 5C).
As epilepsy and seizures are a predominant feature in the
four affected individuals, we performed EEG measure-
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Figure 3. GOT Expression and Activity
(A) Western blot showing GOT2 and the
mitochondrial fraction marker SDHA (suc-
cinate dehydrogenase complex flavopro-
tein subunit A) in the GOT2-deficient indi-
viduals, GOT2 carriers, and two control
fibroblast lines.
(B) Western blot for GOT2 protein in
GOT2 wild-type and the three GOT2-
knockout HEK293 cell lines.
(C) GOT2 activity in mitochondria-en-
riched fractions from fibroblasts from the
GOT2-deficient individuals, GOT2 carriers,
and three healthy control subjects. Graph
bars represent mean5 SD.
(D) Total GOT (GOT1 and GOT2 isoforms)
activity in whole-cell lysates; results are
representative of two independent experi-
ments.
(E) GOT2 activity in the mitochondria-
enriched fractions of GOT2-WT and the
three GOT2-knockout HEK293 cell lines;
results are representative of two indepen-
dent experiments.
(F) GOT2 rescue experiment in fibroblasts
from individual 1. GOT2 activity is restored
to control levels when GOT2-deficient
fibroblasts are transduced with the GOT2
wild-type gene. Five control fibroblast lines
and the GOT2-deficient fibroblasts trans-
duced without GOT2 wild-type (þ GFP
lane) were used for comparison.
ments on zebrafish got2a morphants.
This showed seizure-like spikes when
the electrical probe was placed in the
forebrain (Figure 5D) but not when
placed in the midbrain (data not
shown). Interestingly, the frequency
of the seizure-like spike discharge
events in got2a morphants was rescued by supplying PN
in the water of the developing embryos as demonstrated
by 5 min EEG recording (Figure 5E, left), whereas duration
of the events was rescued partially by PN (Figure 5E, right),
further supporting the therapeutic strategies in affected
individuals.
Discussion
GOT2 deficiency is a mitochondriopathy and our studies
demonstrate that it is amenable to therapeutic interven-
tion. Further experience on more affected persons is
needed to confirm this. Clinically it presents as an early-
onsetmetabolic encephalopathywith epilepsy, progressive
microcephaly, and several biochemical abnormalities.
GOT2 deficiency adds to the short list of mitochondriopa-
thies responding to a specific pharmacological interven-
tion.30 If confirmed on other persons, GOT2 deficiency
will expand the list of treatable metabolic epilepsies,
recently reported 73 in number,31 as well as the growing
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group of pyridoxine and/or pyridoxal 50-phosphate
responsive epilepsies (ALDH7A1, PNPO, PLPBP, ALPL
[MIM: 107323, 603287, 604436, 171760]).32 The impor-
tance of a thorough metabolic workup including a diag-
nostic and therapeutic trial with pyridoxine and the active
cofactor pyridoxal 50-phosphate cannot be overempha-
sized. In each of the three families a child died either
during pregnancy, at birth, or at very young age. All
affected individuals in this study have some residual
GOT2 enzymatic activity, which is probably essential for
viability. Stillbirth and early childhood death may occur
in families with more severe bi-allelic GOT2 mutations,
as also suggested by the homozygous Got2-knockout
mice which were not viable and by the embryonic death
which was observed in the zebrafish model. GOT2-
deficient individuals share a phenotype of epilepsy, intel-
lectual disability, and several biochemical features with
persons suffering from other MAS defects (MDH2,
SLC25A12, SLC25A13).9,33,34 GOT2 deficiency clinically
also resembles the three known inborn errors of serine
metabolism (genes involved: PHGDH, PSAT1, PSPH [MIM:
606879, 610936, 172480]) with microcephaly, intellectual
developmental disorder, and epilepsy. GOT2 deficiency
should be considered in the differential diagnosis of
epileptic encephalopathy especially in the presence of
high lactate, increased ammonia and citrulline, and
decreased serine. Theoretically other MAS defects may
also lead to secondary decreased serine synthesis due to
cytosolic redox imbalance but low serine levels have not
yet been reported in such case subjects.
Western blot and enzyme activity data show that
the GOT2 mutations in our affected individuals prevent
GOT2 expression or render the GOT2-protein unstable.
GOT2 deficiency impacts the malate-aspartate shuttle
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Figure 4. De novo Serine Biosynthesis in
Mutant Fibroblasts and GOT2-Knockout
HEK293 Cells
(A) 13C3-serine fractions were determined
in fibroblasts of GOT2-deficient cases, the
two GOT2 carriers, six healthy control sub-
jects, and two individuals with a de novo
serine biosynthesis defect (3-PGDHD and
PSATD deficiencies). Fibroblasts were incu-
bated with 13C6-glucose, and the forma-
tion of the labeled 13C3-serine was
analyzed at t ¼ 0, 0.5, 4, and 10 h after
exposure. The results are normalized to
total protein content and represented as
the mean of n ¼ 3 5 SD for individual 4
and carrier 2, PSATD deficiency and
3-PGDHD deficiency; n ¼ 65 SD for indi-
viduals 1, 2, and 3, and carrier 1; and
n ¼ 335 SD for control subjects.
(B) 13C3-serine and
13C2-glycine fractions
were determined in GOT2-WT (full line)
and the GOT2-knockout HEK293 cell lines
(dashed line). Cells were incubated with 13
C6-glucose, and the formation of the
labeled 13C3-serine and
13C2-glycine was
analyzed at t ¼ 0, 0.5, 4, and 10 h after
exposure. The results are representative of
two independent experiments and are
normalized to total protein content and
represented as the mean of n ¼ 3 (biolog-
ical triplicates) 5 SD.
(C) To study the impact of glycerol and py-
ruvate supplementation in de novo serine
production of the GOT2-knockout cell
lines, we supplemented the cells with
these compounds (2.5 and 5 mmol/L) for
4 h. The formation of labeled 13C3-serine
was analyzed at t ¼ 0, 0.5, and 4 h after
exposure. The results are normalized to
total protein content and represented as
the mean of n ¼ 35 SD.
(D) The same study was performed for
glycine. The formation of labeled 13C2-
glycine was analyzed at t ¼ 0, 0.5, and
4 h after exposure. The results are normal-
ized to total protein content and repre-
sented as the mean of n ¼ 35 SD.
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Figure 5. Knockdown of got2a in Zebrafish Perturbs Brain and Embryonic Development and Function, which Can Be Rescued by
Pyridoxine and Serine
(A) Phenotype severity and rescue scoring system for got2a knockdown embryos. Bright field images of 3 day post fertilization (dpf) WT
embryos injected with control morpholino (Cont MO) and/or got2a ATG blocking morpholino (got2a MO). The got2amorphants were
scored in five different categories (P1 to P5) based on the phenotype severities.
(B) Pyridoxine, serine, and pyruvate decrease got2a morphant’s phenotype severity. Number of larvae per condition were shown in
parentheses. 2 nL of morpholino (0.4 mM working solution) was injected. Compounds were added at 6 h post-fertilization (hpf) in
24-well plates. Every 24 h, dead embryos were removed and the compounds were replaced with fresh solution. Phenotype was charac-
terized at 3 dpf. For phenotype severity calculation, the following ‘‘phenotype scores’’ were used: P0, normal: 0; P1, small brain, enlarged
yolk, andmild cardiac edema: 1; P2, smaller brain, enlarged yolk, mild cardiac edema, and shortened body: 2; P3, smaller brain, enlarged
(legend continued on next page)
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and subsequently the overall cellular NADH/NADþ ratio
with consequences for NAD-dependent enzymes and path-
ways. Elevated blood lactate concentrations of the affected
individuals can be explained as direct consequence of the
impaired re-oxidation of cytosolic NADH due to the defec-
tive MAS. Interestingly, hyperlactatemia is also present in
MDH2 deficiency, another disorder impairing the MAS
(Figure 1).9
All four affected individuals had a mild but persistent
hyperammonemia, with individual 1 also having mild
hypercitrullinemia. Both can be explained by a secondary
urea cycle defect in GOT2 deficiency. In humans, the
amount of aspartate taken up from the blood is very
low,35 rendering cells highly dependent on their mitochon-
drial aspartate production. In GOT2 deficiency, the intrami-
tochondrial synthesis of aspartate from oxaloacetate is
decreased, leading to lower concentrations of aspartate in
the mitochondrion and the cytosol. In one of the cyto-
plasmic steps of the urea cycle in liver, the enzyme arginino-
succinate synthetase requires aspartate as a substrate.
Aspartate shortage leads to reduced argininosuccinate
synthesis, and to citrulline accumulation, with hyperam-
monemia as a final consequence of diminished urea cycle
activity.6
A further striking observation in individual 1 was a
consistently reduced plasma serine concentration in the
same range as observed in individuals with serine biosyn-
thesis defects. No mutations were found in genes
implicated in the biosynthesis of serine. Stable isotope-
labeling studies showed decreased serine synthesis from
13C6-glucose in fibroblasts of affected individuals and in
GOT2-knockout HEK293 cells. Intracellular serine can
originate from four sources: (1) the diet, (2) de novo biosyn-
thesis, (3) glycine, or (4) protein and phospholipid degra-
dation.36 The first reaction in de novo serine biosynthesis
is catalyzed by the NADþ-dependent enzyme 3-phospho-
glycerate dehydrogenase. The low serine and glycine pro-
duction observed in GOT2 deficiency is most likely due
to an increased NADH/NADþ ratio as a consequence of
a dysfunctional MAS. Pyridoxine is essential for serine
de novo biosynthesis,37 so we cannot exclude that the
mechanism of pyridoxine responsiveness may be partly
due to a direct effect on boosting serine synthesis by a
mechanism other than restoring the NADH/NADþ redox
balance.
To investigate whether correction of the cytosolic
NADH/NADþ ratio could restore serine and glycine de
novo synthesis, we supplemented the culture medium of
GOT2-deficient HEK293 cells with glycerol or pyruvate.
The rationale behind glycerol addition was to stimulate
the activity of the glycerol 3-phosphate shuttle, a second
system for the regeneration of NADþ from NADH. No
effect of glycerol on serine and glycine synthesis was
observed, suggesting that the MAS is the predominant
NAD(H) redox shuttle, at least in HEK293 cells. After incu-
bating with pyruvate, which is enzymatically reduced to
lactate in the cytosol while re-oxidizing NADH to NADþ,
complete normalization of serine and glycine synthesis
was observed, supporting our hypothesis that serine
biosynthesis is hampered by the impaired cytosolic redox
imbalance. GOT2 deficiency is a mitochondriopathy
with metabolic consequences in mitochondria and in
the cytoplasm due to redox imbalance. Our data explain
the mitochondrial pathomechanism and clarify how
GOT2 deficiency impacts serine biosynthesis and
possibly other NAD(H)-dependent reactions and how the
affected individuals benefit from serine and/or pyridoxine
supplementation.
Individual 1 was free of seizures only when a combina-
tion of serine and pyridoxine was administered. PLP is an
obligatory co-activator for all transaminases, including
GOT2. It may stimulate residual GOT2 activity possibly
by improving the proper folding of GOT2.
Interestingly, the only other individual with uncon-
trolled seizures (individual 4) was put on pyridoxine-only
therapy for 8 months. His epilepsy was better controlled
and his cognitive functions and alertness improved.
Once serine supplementation was added to the treatment
regimen, his seizures were fully controlled with better
cognition and improved physical activity. In a period
that serine was unavailable, the seizures returned and dis-
appeared again when serine was reintroduced. Treatment
could not be started in individuals 2 and 3.
Theoretically, pyruvate supplementation might be
considered as treatment strategy. Re-oxidation of cytosolic
NADH by pyruvate supplementation in vitro led to full
yolk, severe cardiac edema, and curved body: 3; P4, very small brain, enlarged yolk, very severe cardiac edema, deformed tail, and round
body shape: 4; P5, dead: 5. Average phenotype severity¼P n x (Phenotype score) / N. n, number of embryos showing a specific pheno-
type in a well; N, total initial number of embryos in a well. Treated samples were compared to non-treated conditions using one-way
ANOVA test (*p < 0.05; **p < 0.01; ns, not significant).
(C) Pyridoxine and serine increase the survival of got2amorphants at 2 dpf. Number of larvae per condition is shown in parentheses. 4 nL
of morpholino (0.8 mM working solution) was injected. Compounds were added at 6 h post-fertilization (hpf) in 24-well plates. Every
24 h, dead embryos were removed and the compounds were replaced with fresh solution. The ratio of alive to total number of larvae was
counted and survival percentage calculated at 2 dpf (a dead zebrafish embryo defined as having no heartbeat and no response to stimuli).
Treated samples were compared to non-treated conditions using one-way ANOVA test (*p < 0.05; ns, not significant).
(D) got2a knockdown provoked seizure-like EEG spikes in the forebrain that are rescued by treatment with pyridoxine in 48 hpf embryos.
Newly fertilized zebrafish embryos are injected with control morpholino (Cont MO) or got2a splicing morpholino (sp-MO). Embryos
injected with got2a sp-MO showed EEG spike discharges, not present in traces from embryos injected with Cont MO.
(E) Analysis of EEG traces. Number of events in 5 min recordings and the duration of each event in seconds (sec) in embryos injected
with Cont MO, got2a sp-MO, and got2a sp-MO and treated with pyridoxine. Each event corresponds to a single spike discharge. Bars
represent the mean5 SEM. N ¼ 3 embryos per treatment. *p < 0.05 and ***p < 0.001.
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correction of serine biosynthesis in GOT2-deficient cells.
This effect is explained by the pyruvate-induced correction
of the highNADH/NADþ ratio in the cytosol. Interestingly,
administration of sodium pyruvate with L-arginine proved
effective in treating a person with a defect in SCL25A13.38
Increased lactate formation from pyruvate may form an
unwanted side-effect of this approach. Defects in the
MAS-system only affect the oxidation of cytosolic NADH
and not of intramitochondrial NADH, which implies that
the best therapy strategy would be to provide substrates
that do not produce NADH in the cytosol, e.g., fatty acids
especially medium chain triglycerides. For GOT2-deficient
individuals, we suggest a diet low in carbohydrates, high in
fat, and supplemented with ketone bodies that circum-
vents the issue of acidification due to lactate production.
Our zebrafish modeling of GOT2 deficiency demonstrated
that serine and pyridoxine treatment would likely deliver a
synergetic effect. These could be further explored as thera-
peutic strategies in disease management.
Future research on this MAS defect should focus on the
identification of more affected individuals, characteriza-
tion of the full phenotypic and genotypic spectrum, iden-
tification of biomarkers and other treatment targets, as well
as implementation and evaluation of therapeutic interven-
tions in more case subjects.
Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
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